Papillomavirus-like particle vaccines.

  title={Papillomavirus-like particle vaccines.},
  author={John T. Schiller and Douglas R Lowy},
  journal={Journal of the National Cancer Institute. Monographs},
Papillomavirus-like particle (VLP)-based subunit vaccines have undergone rapid development over the past 8 years. Three types are being investigated. The most basic type is composed of only the L1 major capsid protein and is designed to prevent genital human papillomavirus (HPV) infection by inducing virus-neutralizing antibodies. On the basis of positive results in animal models, clinical trials of this type of vaccine for HPV16, and other types, are currently under way. Preliminary results… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 31 extracted citations

Progress on new vaccine strategies against chronic viral infections.

The Journal of clinical investigation • 2004
View 3 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 32 references

Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection

K Schafer, M Muller, +3 authors H Zentgraf
Int J Cancer 1999;81:881–8 • 1999

Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles.

Proceedings of the National Academy of Sciences of the United States of America • 1999

Similar Papers

Loading similar papers…